Literature DB >> 17053495

Update on treatment of pulmonary exacerbations in cystic fibrosis.

Alan Smyth1.   

Abstract

PURPOSE OF REVIEW: This review will define pulmonary exacerbations in cystic fibrosis and explain their importance in the pathophysiology and progression of this condition. I will stress the importance of prevention, where this is possible, and prompt treatment, where prevention has failed. The management of chronic pulmonary infection with Pseudomonas aeruginosa will be discussed, together with other, less tenacious organisms. RECENT
FINDINGS: Developments in the treatment of chronic pulmonary infection with P. aeruginosa include new data on antibiotic selection through sensitivity testing and alternative antibiotic dosing regimens. Therapies which target the P. aeruginosa biofilm will be discussed, including those which are currently in use (such as azithromycin) as well as those being evaluated in preclinical studies. Supportive care and the role of noninvasive ventilation are discussed.
SUMMARY: The prevention and prompt treatment of pulmonary exacerbations is a central component of cystic fibrosis care.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17053495     DOI: 10.1097/01.mcp.0000245711.43891.16

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  9 in total

1.  In vitro activity of fusidic acid (CEM-102, sodium fusidate) against Staphylococcus aureus isolates from cystic fibrosis patients and its effect on the activities of tobramycin and amikacin against Pseudomonas aeruginosa and Burkholderia cepacia.

Authors:  Pamela McGhee; Catherine Clark; Kim Credito; Linda Beachel; Glenn A Pankuch; Peter C Appelbaum; Klaudia Kosowska-Shick
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

Review 2.  Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.

Authors:  Sherie Smith; Nicola J Rowbotham; Edward Charbek
Journal:  Cochrane Database Syst Rev       Date:  2022-08-01

Review 3.  Clinical and laboratory evidence for Neisseria meningitidis biofilms.

Authors:  R Brock Neil; Michael A Apicella
Journal:  Future Microbiol       Date:  2009-06       Impact factor: 3.165

4.  Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.

Authors:  Jeffrey S Wagener; Lawrence Rasouliyan; Donald R VanDevanter; David J Pasta; Warren E Regelmann; Wayne J Morgan; Michael W Konstan
Journal:  Pediatr Pulmonol       Date:  2012-08-08

Review 5.  Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review.

Authors:  Rosa María Girón Moreno; Marta García-Clemente; Layla Diab-Cáceres; Adrián Martínez-Vergara; Miguel Ángel Martínez-García; Rosa Mar Gómez-Punter
Journal:  Antibiotics (Basel)       Date:  2021-04-23

6.  Streptococcus pneumoniae Strains Isolated From a Single Pediatric Patient Display Distinct Phenotypes.

Authors:  Hannah N Agnew; Erin B Brazel; Alexandra Tikhomirova; Mark van der Linden; Kimberley T McLean; James C Paton; Claudia Trappetti
Journal:  Front Cell Infect Microbiol       Date:  2022-03-31       Impact factor: 6.073

Review 7.  Beneficial and Harmful Interactions of Antibiotics with Microbial Pathogens and the Host Innate Immune System.

Authors:  Ronald Anderson; Gregory Tintinger; Riana Cockeran; Moliehi Potjo; Charles Feldman
Journal:  Pharmaceuticals (Basel)       Date:  2010-05-25

8.  Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.

Authors:  Sherie Smith; Nicola J Rowbotham; Edward Charbek
Journal:  Cochrane Database Syst Rev       Date:  2018-10-30

9.  Role of C-reactive protein as a biomarker for prediction of the severity of pulmonary exacerbations in patients with cystic fibrosis.

Authors:  Rosa Maria Girón-Moreno; José L Justicia; Sara Yamamoto; Claudia Valenzuela; Carolina Cisneros; Rosa Mar Gómez-Punter; Gilda Fernandes-Vasconcelos; Julio Ancochea
Journal:  BMC Pulm Med       Date:  2014-09-23       Impact factor: 3.317

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.